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P-glycoprotein (P-gp) is a membrane protein associated with multidrug resistance (MDR)
due to its key role in mediating the traffic of chemotherapeutic drugs outside cancer
cells, leading to a cellular response that hinders efforts toward successful therapy. With
the aim of finding agents that circumvent the MDR phenotype mediated by P-gp, 15
compounds isolated from native and naturalized plants of Argentina were screened.
Among these, the non-cytotoxic lignan (±) pinoresinol successfully restored sensitivity to
doxorubicin from 7 µM in the P-gp overexpressed human myelogenous leukemia cells,
Lucena 1. This resistance-reversing effect was confirmed by competitively increasing
the intracellular doxorubicin accumulation and by significantly inhibiting the efflux of
doxorubicin and, to a lesser extent, that of rhodamine 123. The activity obtained was
similar to that observed with verapamil. No such results were observed in the sensitive
parental K562 cell line. To gain deeper insight into the mode of action of pinoresinol,
its effect on P-gp function and expression was examined. The docking simulations
indicated that the lignan bound to P-gp at the apex of the V-shaped transmembrane
cavity, involving transmembrane helices 4, 5, and 6, and partially overlapped the binding
region of tariquidar, which was used as a positive control. These results would shed
some light on the nature of its interaction with P-gp at molecular level and merit further
mechanistic and kinetic studies. In addition, it showed a maximum 29% activation of ATP
hydrolysis and antagonized verapamil-stimulated ATPase activity with an IC50 of 20.9
µM. On the other hand, pinoresinol decreased the presence of P-gp in the cell surface.
Derivatives of pinoresinol with improved activity were identified by docking studies. The
most promising one, the non-cytotoxic 1-acetoxypinoresinol, caused a reversion of
doxorubicin resistance from 0.11 µM and thus higher activity than the lead compound.
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It also caused a significant increase in doxorubicin accumulation. Results were similar
to those observed with verapamil. The results obtained positioned these compounds as
potential candidates for effective agents to overcome P-gp-mediated MDR, leading to
better outcomes for leukemia chemotherapy.
Keywords: multidrug resistance reversal, P-glycoprotein, plant-derived compounds, (±) pinoresinol, 1-acetoxy-
(+)-pinoresinol
INTRODUCTION
The P-glycoprotein (P-gp) transporter (ABCB1/MDR1) encoded
by the MDR-1 gene is a protein located in the cell membranes
of various tissues involved in the traffic of substrates outside
the cells (Sharom, 2011; Silva et al., 2015). In a considerable
number of cancers, high levels of MDR-1 expression provide the
most commonly encounteredmechanism ofmultidrug resistance
(MDR) (Shin et al., 2006), representing a major obstacle to the
success of chemotherapy (Siarheyeva et al., 2010).
P-glycoprotein (P-gp) is comprised of two homologous
transmembrane domains (TMDs). Each half consists of
six transmembrane α-helices (TMHs) and one cytoplasmic
nucleotide-binding domain (NBD), which fuel the energy from
ATP hydrolysis, leading to conformational changes that result in
the extrusion of a set of structurally and functionally unrelated
chemotherapy drugs against their concentration gradient
(Sharom, 2011). As a consequence, P-gp keeps intracellular
drug accumulation low, leading to a cellular responsiveness
known as classical MDR (Krishna and Mayer, 2000). This
phenomenon and the broad spectrum of substrates removed
from cells, such as paclitaxel, etoposide, teniposide, vinblastine,
vincristine, doxorubicin, daunorubicin, and imatinib among
others (Kathawala et al., 2015), makes this pump one of the most
significant transporters in pharmacology (Saeed M. E. M. et al.,
2015).
Almost half of human tumors show the ability to express
P-gp (Fu and Arias, 2012). Not only failures in chemotherapy
but also poor overall prognosis are strongly linked to increased
levels of the MDR-1 product in many cancers (Loo and Clarke,
1999), including certain types of leukemia (Szakacs et al., 2006;
Vasconcelos et al., 2011; Rumjanek et al., 2013). Leukemia is a
malignant disorder with a significant number of deaths annually
(Lin et al., 2011). Based on GLOBOCAN, about 352,000 new
cases of leukemia and 265,000 deaths occurred worldwide in
2012 (Ferlay et al., 2015). Overexpression of P-gp was detected
in about 50% of patients with chronic myelogenous leukemia
(CML) unresponsive to chemotherapy with Vinca alkaloids and
anthracyclines (Kuwazuru et al., 1990).
Strategies to overcome MDR include the development of P-gp
function inhibitors that may act by blocking the substrate binding
Abbreviations: P-gp, P-glycoprotein; MDR, multidrug resistance; TMD,
transmembrane domains; TMH, transmembrane α-helices; CML, chronic
myelogenous leukemia; MTT, 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide; VLB, vinblastine sulfate; CsA, cyclosporine A; TFP,
trifluoperazine; DOX, doxorubicin; MEC, minimum effective concentration; Rho
123, rhodamine 123; NBD, nucleotide-binding domain; PBMC, peripheral blood
mononuclear cells.
to the protein, by interacting with an allosteric region of P-gp
preventing the eﬄux or by interfering with the ATP hydrolysis.
Alternatively, inhibitors may act by indirect mechanisms, like
hindering P-gp phosphorylation or disturbing the integrity of the
cell membrane lipids (Wink, 2012; Silva et al., 2015). Interference
with the surface expression of P-gp is proposed as another valid
strategy for restoring drug effectiveness (Ferrándiz-Huertas et al.,
2011; Fu and Arias, 2012).
Although some of the reversal agents submitted to clinical
trials succeed in some patients (List et al., 2001), most of
them failed in many aspects to prove their effectiveness as
MDR reversers (Wink, 2012; Lei et al., 2013), particularly in
their adverse effects, interactions with the drug administered in
parallel and inadequate trial designs (List et al., 2001; Szakacs
et al., 2006; Steinbach and Legrand, 2007; Wu et al., 2011; Xia
et al., 2015).
A great deal of research therefore focuses on the search for
agents devoid of these undesired effects and able to reverse the
MDR/P-gp phenotype.
Plants constitute an important source of bioactive molecules
with a significant contribution to cancer chemotherapy (Gosh
et al., 2009) including P-gp inhibitors (Palmeira et al., 2012a).
The exceptional structural diversity of plant-derived metabolites
offers a great range of possibilities for finding novel modulators
of this target. As observed with substrates, P-gp chemosensitizers
can be structurally distinct (Eid et al., 2015), with a diversity of
plant compounds belonging to different chemical families that
are capable of suppressing P-gp-mediated transport (Efferth et al.,
2002; Katayama et al., 2007; Nabekura et al., 2008; Han et al.,
2011; Wink, 2012; Eid et al., 2013; Lei et al., 2013; Sun and Wink,
2014; Zeino et al., 2015). These entities, together with compounds
from other natural sources, are known as fourth-generation
inhibitors (Wu et al., 2011).
Even though many compounds with medicinal properties
have been obtained from Argentine flora (Chiari et al., 2010,
2011; Carpinella et al., 2011; Joray et al., 2011, 2013), this resource
is far from being completely explored, especially for compounds
with MDR reversal properties. It is considered that only 1% of
the 9,690 species of Argentine vascular flora have been studied.
Among these species, mainly belonging to Asteraceae, Poaceae
and Fabaceae, 1,200 are known to possess medicinal properties
(Zuloaga et al., 1999; Alonso and Desmarchelier, 2015).
With this in mind, we screened a panel of bioactive
metabolites obtained from native and naturalized plants from
central Argentina on P-gp overexpressed leukemia cells. Assays
were performed focused on the modes of action of the
most effective compound, pinoresinol, including studies of the
binding site of this active principle on P-gp by molecular
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modeling. The lignan (±)-pinoresinol was previously isolated
in our laboratory from the naturalized tree, Melia azedarach
as an antifungal compound (Carpinella et al., 2003). It was
able to decrease the effective concentrations of the synthetic
antifungal agents mancozeb and carboxin, even when these
were applied at 5 and 3% of their corresponding minimum
inhibitory concentrations (Carpinella et al., 2005). Pinoresinol
also showed anti-inflammatory, antioxidant, neuroprotective,
and hypoglycemic properties (López-Biedma et al., 2016) and
exhibited different levels of cytotoxic effect depending on the
tumor cells (Moon et al., 2008; López-Biedma et al., 2016).
Few in vivo studies have been performed and these have
concentrated on the anti-inflammatory, antioxidant, antitumor,
and neuroprotective effect of the lignan (Torres-Sanchez et al.,
2009; Kim et al., 2010; Lapi et al., 2015).
In addition, a pinoresinol derivative, showing improved
activity in relation to pinoresinol in docking simulations,
showed experimentally an outstanding reversing activity on P-gp
transport, with higher effectiveness than the lead compound.
MATERIALS AND METHODS
Chemicals, Equipment, and Reagents
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT), vinblastine sulfate (VLB, 96%), cyclosporine
A (CsA, 98.5%), trifluoperazine dihydrochloride (TFP, 99.0%),
histopaque 1077, rhodamine 123 (Rho 123), and lectin from
Phaseolus vulgaris (PHA) were purchased from Sigma-Aldrich
Co (St Louis, MO). Doxorubicin hydrochloride (DOX, 99.8%,
Synbias Pharma Ltd.) was obtained from Nanox Release
Technology (Buenos Aires, Argentina) and was used dissolved
in bi-distilled water. Verapamil hydrochloride 98% was provided
by Parafarm (Buenos Aires, Argentina) and was used as the
reference P-gp inhibitor dissolved in ethanol at 30 µM. RPMI-
1640 and Gibco R© cell culture reagents were purchased from
Invitrogen Life Technologies (Carlsbad, CA). Sterile plastic
material was purchased from Greiner Bio-One (Frickenhausen,
Germany). All solvents were HPLC grade.
FITC mouse anti-human (P-gp) was purchased from BD
(BD Biosciences, USA). MDR1 PREDEASYTM ATPase assay
kit was obtained from Solvo Biotechnology (Szeged, Hungary).
Flow cytometry was performed in a Becton Dickinson (BD)
FACSCanto II flow cytometer (BD Biosciences, USA).
Compounds 1–15 (Figure 1) were previously isolated in the
laboratory from native and naturalized plants from Argentina.
They were tested at 90% or higher purity, determined by
HPLC. The compounds assayed were: vanillin (1) and, 4-
hydroxy-3-methoxycinnamaldehyde (2), both isolated from
Melia azedarach (Carpinella et al., 2003), ilicol (3) isolated from
Flourensia oolepis (Diaz Napal and Palacios, 2013), scopoletin
(4) obtained from M. azedarach (Carpinella et al., 2005),
(Z,Z)-5-(trideca-4,7-dienyl)-resorcinol (5) isolated from Lithrea
molleoides (Carpinella et al., 2011), 2′,4′-dihydroxychalcone
(6) and (-)-pinocembrin (7) both obtained from F. oolepis
(Diaz Napal et al., 2009; Joray et al., 2015), naringenin (8)
isolated from Baccharis salicifolia (Céspedes et al., 2006; del
Corral et al., 2012), dalenin (9) obtained from Dalea elegans
(Chiari et al., 2011), apigenin (10) isolated from B. salicifolia
(del Corral et al., 2012), quercetin (11), 3-O-methylquercetin
(12), and 23-methyl-6-O-desmethylauricepirone (13) obtained
from Achyrocline satureioides (Joray et al., 2011, 2013) and
(±)-pinoresinol (14) and meliartenin (15) both obtained from
M. azedarach (Carpinella et al., 2002, 2003). 1-acetoxy-(+)-
pinoresinol (16) (Figure 1) was purchased from Chem Faces
(Wuhan, PR). The 1H, 13C, 2D-NMR spectra, and HPLC
chromatograms of the compounds are available upon request
from the authors.
Cell Lines and Cell Culture
The K562 human CML cell line (Rumjanek et al., 2013) and its
MDR counterpart, Lucena 1, were used (Moreira et al., 2014).
Lucena 1 was chosen as a well-characterized resistant cell line
in which P-gp overexpression is the exclusive mechanism of
acquired resistance (Moreira et al., 2014). Real time quantitative
PCR analysis for P-gp andMRP1 showed no statistical differences
between cells maintained with vincristine and those maintained
with doxorubicin. Both lines were routinelymaintained in RPMI-
1640 medium supplemented with 10% fetal bovine serum, 2
mM L-glutamine, 100 U mL−1 penicillin and 100 µg mL−1
streptomycin in a 5% CO2 humidified atmosphere at 37◦C.
Cells were subcultured twice a week and used when under 20th
passage from frozen stocks. Lucena 1 cells were cultured in the
presence of 60 nM of DOX to maintain P-gp overexpression,
until 4 days before the experiments, when they were transferred
to drug-free medium. These cells displayed a higher superficial
P-gp expression than parental K562 cells (see Figure 2). All
experiments were performed with the cells in the logarithmic
growth phase with cell viabilities above 90% determined by
staining with trypan blue.
Multidrug Resistance Reversal Assay
Compounds 1–15 and then compound 16, which was
selected after demonstrating lower binding energy than its
lead compound 14 and other pinoresinol derivatives, were
screened by MTT colorimetric assay for their ability to reverse
cellular resistance to DOX. Briefly, 5 × 104 Lucena 1 cells
per well were seeded in 96-well plates containing RPMI-1640
medium in the presence of DOX alone or in combination with
the tested compounds dissolved in ethanol or acetonitrile as
appropriate. DOX was added to reach final concentrations of
0.05–431 µM. The compounds were assayed at the highest
non-toxic concentration observed in both cell lines (cytotoxicity
≤ 20%, Cytotoxicity (%) = [1-(Optical density treatment-
Optical density DMSO)/(Optical density control-
Optical density DMSO)] x 100, determined byMTT proliferation
assay (Joray et al., 2015); maximum concentration tested 40
µg mL−1). Following the primary screening, compounds 14
and 16 (dissolved in ethanol) were tested at serial dilutions.
Negative controls containing only bi-distilled water, ethanol or
acetonitrile (1% v/v since no adverse effects were observed at
this concentration) were simultaneously run as well as viability
controls with no addition of the dissolution solvents. Verapamil
was used as a positive control at 30, 0.11 and 0.055 µM. After 48
h incubation at 37◦C with 5% CO2, 20 µL of 5mg mL−1 MTT
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FIGURE 1 | Chemical structures of compounds 1–16.
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FIGURE 2 | P-gp surface expression in (A) Lucena 1 and (B) K562 cells determined by flow cytometry. Unstained cells are shown with red histogram while
FITC-conjugated mouse anti-human P-gp antibody stained cells are shown with blue histogram. Histograms are representative of three independent experiments.
solution in sterile PBS was added to each well and incubation
continued for 4 h. Subsequently, the supernatants were removed
and replaced with 100 µL DMSO to solubilize the resulting
purple formazan crystals produced from metabolically viable
cells. Absorbance was measured with an iMark micro-plate
reader (Bio-Rad, USA) at 595 nm.
Half inhibitory concentrations (IC50) represent the
concentrations of DOX required to inhibit 50% of cell
proliferation (compared to the solvent controls, which showed
no differences in comparison to viability controls) and were
calculated from the mean values of data from wells.
The same reversal assay was performed in K562 cells, in order
to discard a decrease in the IC50 of DOX due to effects other
than P-gp inhibition. The reversal fold (RF) values for the tested
compounds, which indicate their capacity to reduce resistance to
DOX, were calculated by dividing the IC50 of DOX alone by the
IC50 of DOX in the presence of the tested compounds (Xu et al.,
2014).
The assays were also performed with VLB, which was
added, dissolved in DMSO at 2 × 10−5 to 44 µM alone
or in combination with 14 at 112 µM. The negative control
contained DMSO, while verapamil was used as the reference
compound.
Doxorubicin Intracellular Accumulation
Assays
The effect of 14 or 16 on DOX intracellular accumulation was
further studied.
In order to establish the best assay conditions, 2.5 × 105
Lucena 1 or K562 cells mL−1 were seeded onto 24-well plates and
pre-incubated in complete RPMI-1640 medium in the presence
of 112 µM of 14 (dissolved in ethanol), verapamil or ethanol (1%
v/v) from 0 to 48 h at 37◦C with 5% CO2. Following incubation,
5 µMDOX was added and cells were further incubated for 1 h.
Time course of DOX accumulation was investigated by
co-incubating 2.5 × 105 Lucena 1 or K562 cells mL−1 with 112
µM of 14 or 1% ethanol in 96-well plates for 1 h at 37◦C prior to
the addition of 5 µMDOX. The intracellular DOX was measured
at increasing periods of time.
To obtain further information about the type of inhibition
exerted by compound 14, the kinetic behavior was analyzed
by the Lineweaver-Burk double-reciprocal method compared to
data obtained in the absence of the inhibitor (ethanol control)
(Arnaud et al., 2010). The drug retention rate corresponding
to the amount of DOX remaining inside 50,000 Lucena 1 cells
after 1 h incubation was plotted vs. DOX concentrations and
fitted with the Michaelis-Menten equation, R = Rmax [S]/Km +
[S], where R is the drug retention rate, Rmax the maximal drug
retention rate, [S] is the substrate concentration and Km the
Michaelis constant of DOX eﬄux (Copeland, 2000; Arnaud et al.,
2010).
With the aim of determining the minimum effective
concentration (MEC) of 14 or 16, 2.5 × 105 Lucena
1 or K562 cells mL−1 were incubated with 7–112 or
0.027–14 µM of each compound, respectively, for 1 h at
37◦C with 5% CO2. Afterwards, 5 µM solution of DOX
was added and the plates were further incubated for 1 h.
Verapamil or ethanol (1%) were run as positive and negative
controls, respectively. Viability controls were included in all the
experiments.
After DOX incubation in all the assays described, cells were
placed on ice to stop the reactions, followed by washing twice
with ice-cold PBS. The intracellular DOX-associated fluorescence
of 50,000 individual cells was determined by FACScan flow
cytometry. DOX was excited at 488 nm and the emitted light
was collected with a 585/42 nm bandpass filter. Dead cells and
cell debris were excluded by forward and side scatter gating.
Mean fluorescence intensities (MFI) were analyzed with Flowjo
software (Tree Star, Inc. Ashland, OR).
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The data collected was compared to that obtained with 30 µM
verapamil (which was considered as the maximum inhibition)
and expressed as the published equation (Huang et al., 2013):
% of Inhibition =
[ (
MFI of cells treated with 14 or 16 − MFI of negative control
)
(
MFI of cells treated with verapamil − MFI of negative control
)
]
× 100
With the aim of discarding fluorescence by the compounds
themselves, flow cytometry of 14 or 16 was performed at the
maximum concentration tested in the absence of DOX. No
fluorescence due to these compounds was observed.
Doxorubicin Efflux Assay
To determine the effect on DOX eﬄux, 2.5 × 105 Lucena 1 or
K562 cells mL−1 were first pre-incubated in 24-well plates in the
presence of 14, dissolved in ethanol at 112 µM, verapamil or
ethanol (1% v/v) for 1 h at 37◦C with 5% CO2. After incubation,
DOX 5 µM was added to the reaction mixture and further
incubated for 1 h. Subsequently, cells were washed with cold PBS
and incubated for different times with 14, verapamil or ethanol
in DOX-free medium to allow dye extrusion. With the aim of
determining the minimum effective concentration (MEC) of 14,
2.5 × 105 Lucena 1 cells were incubated with 7–112 µM of
the lignan, for 1 h at 37◦C with 5% CO2. Afterwards, 5 µM
solution of DOXwas added and the plates were further incubated
for 1 h. After washing, cells were incubated for 30 min with
14. Verapamil or ethanol (1%) were run as positive or negative
controls, respectively. Cells were then washed with ice-cold PBS
and the intracellular DOX-associated MFI of 50,000 individual
cells was determined by flow cytometry as previously described.
Rhodamine 123 Efflux Assay
Rho 123, a P-gp fluorescent substrate, is frequently employed
as an indicator of P-gp activity and it was therefore used in
an additional eﬄux study. Briefly, Lucena 1 or K562 cells at a
density of 2.5 × 105 mL−1 were pre-incubated with 14 dissolved
in ethanol at 112 µM (2 × MEC), TFP (8 µM), verapamil or
ethanol (1% v/v) for 1 h at 37◦C with 5% CO2. Subsequently,
cells were incubated with 500 ng mL−1 of Rho 123 for 30min.
After incubation, the medium was removed and the cells were
incubated in Rho 123-free medium with 14, verapamil, TFP and
ethanol, for a further 30min to allow Rho 123 extrusion. After
washing twice with cold PBS, the amount of Rho 123 remaining
in 10,000 individual cells after the eﬄux period was quantified by
FACScan flow cytometry. Excitation was performed with a laser
operating at 488 nm and the emitted fluorescence was collected
through a 530/30 nm pass filter.
Determination of ATPase Activity
The ATPase activity of P-gp was determined using the
PREDEASYTM ATPase assay kit as per the manufacturer’s
recommendation. In the activation assay, increasing
concentrations of 14 (0.27–600 µM) or verapamil (0.14–
300 µM), both dissolved in DMSO (2% final concentration),
were pre-incubated in ATPase assay buffer with membrane
preparations from Spodoptera frugiperda ovarian cells (Sf9)
containing human P-gp and 10 mM MgATP for 10min at 37◦C.
Formonitoring the inhibition of the substrate stimulated-ATPase
activity, verapamil (40 µM) was added to the incubation mixture
as an ABC transporter-related ATPase activator. The ATPase
reaction was subsequently stopped and the inorganic phosphate
(Pi) produced was measured colorimetrically at 630 nm. DMSO
was used as a solvent control and CsA (final concentration of 40
µM) was used as reference inhibitor in the inhibition assay.
All experiments were performed in the absence or presence
of 1.2mM of sodium orthovanadate, an ABC transporter-related
ATPase inhibitor, in order to measure the vanadate-sensitive
portion of the total ATPase activity. ATPase activities were
determined as Activity (%)= (A− B) – (E− F)× 100/(C−D) –
(E− F), where A is the activity in the presence of 14 alone or with
verapamil as activator in the inhibition study, B is the activity
in the presence of 14 alone or with verapamil in the inhibition
study, in the presence of vanadate (background activity), C is
the maximum activation value due to verapamil and D is the
same value as C but with the addition of vanadate (background
activity), E is the activity of control with DMSO while F is the
activity of DMSO in the presence of vanadate. Membranes from
Sf9 cells expressing defective P-gp were used as controls.
Molecular Modeling
The structural model of the P-gp used for the docking studies
was a homology model of the human P-gp previously proposed
in Jara et al. (2013). In this work, this model was subject
to stochastic molecular dynamics for obtaining average inter-
residue distances in good agreement with the experimental
distances and challenged to reproduce the right activity order
of a pool of known inhibitors, as well as to find binding sites
in good agreement with those proposed on computational and
experimental bases in the literature (Jara et al., 2013).
The following probe ligands were docked in the structural
models of the P-gp:
• pinoresinol derivatives, such as 1-acetoxy-(+)-pinoresinol
(16), 1-acetoxy-(−)-pinoresinol (16a), 1-hydroxy-(+)-
pinoresinol, phylligenin, pinoresinol diglucoside and
(+)-pinoresinol 4-glucoside submitted to docking to establish
whether their activity improved with respect to 14.
• compound 2, which was found to be inactive, was used
as a negative control and the powerful inhibitor tariquidar
(XR9570) (Jara et al., 2013) run as positive control, even
though it was not experimentally studied.
• Verapamil, a known inhibitor used as a reference in the
experiments.
• DOX and Rho 123 used as model substrates in the
experiments.
The structures of these ligands were obtained by performing
a conformational search (when relevant) and a full geometry
optimization at the semiempirical PM6 level of theory,
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characterizing the structures as minima by diagonalizing the
Hessian matrix and ensuring the absence of negative eigenvalues;
next, a refinement was made at the PBE0/6-31G∗ level using the
Gaussian 09 (Rev. B01) package (http://www.gaussian.com). The
Autodock 4.2.6 package (Morris et al., 2009) was used for the
docking simulations, precomputing a grid in the interior of the
whole TMD. Considering the large size of the docking region,
2,000 runs of Lamarckian genetic algorithm were performed for
each ligand (Morris et al., 1998, 2009). The population was set
at 150 individuals, up to 105 generations with 1 survivor per
generation and a limit of 6 × 106 energy evaluations and the
remaining algorithm control parameters set to program defaults.
The cluster analysis was made with 2.5Å of RMSD. Molecular
graphics rendering was performed using VMD 1.9.2 (Humphrey
et al., 1996).
Besides the main grid box including the transmembrane
region, molecular docking on the NBDs was carried out to obtain
preliminary information about the presence of direct binding of
14 to the NBDs.
Study on the Surface Expression of P-Gp
To determine the effect of 14 on P-gp surface expression, Lucena
1 or K562 cells at a density of 5 × 104 cells mL−1 were
incubated in the presence of 14, dissolved in ethanol at 112
µM (maximum non-cytotoxic concentration, in order to ensure
the presence of the effect) or 1% ethanol (control) for 24 and
48 h. Then, cells were washed with cold PBS and labeled for
30min at 4◦C in the dark with FITC-conjugated mouse anti-
human P-gp antibody, which binds to an external epitope of
P-gp, according to the manufacturer’s instructions. Finally, cells
were washed and suspended with ice-cold PBS and fluorescence
intensity was determined in 10,000 individual cells by FACScan
flow cytometry. FITC fluorescence was measured at an excitation
wavelength of 488 nm and emitted light was collected with a
530/30 nm bandpass filter.
Cytotoxicity on Peripheral Blood
Mononuclear Cells (PBMC)
The cytotoxicity of 14 and 16 on peripheral blood mononuclear
cells (PBMC) was evaluated by MTT assay (Joray et al., 2015).
PBMCwere collected from fresh heparinized blood and separated
by density gradient centrifugation (Ficoll R©) as described by
Rennó et al. (2008). As the current study required samples
from healthy human volunteer donors, ethical approval was
provided by the Catholic University of Córdoba Research Ethics
Board. Signed informed consents were obtained from donors.
For the cytotoxicity assay, 1 × 105 PBMC/well were incubated
in duplicate in 96-well plates with PHA 10 µg mL−1, in
the presence of increasing concentrations of 14 (28–560 µM),
16 (3.5–315 µM) (both dissolved in ethanol) or 1% ethanol
for 48 h. Absorbance (Abs) and percentage of cytotoxicity
were determined as described above and the IC50 values were
calculated. The experiment was carried out in two separate stages.
Statistical Analysis
The results are expressed as mean ± SE. Data were analyzed
using Student’s t-test or two-way analysis of variance (ANOVA)
using GraphPad Prism software (Graphpad Prism 5.0, Graphpad
Software, Inc., CA, USA), with p≤ 0.05 as statistically significant.
All experiments were performed in duplicate or triplicate at
least three times. The 50% inhibitory concentrations (IC50) were
calculated by log-Probit analysis responding to at least seven
concentrations at the 95% confidence level with upper and lower
confidence limits. The curves from the ATPase assays were fitted
to the relative activity vs. compound 14 concentrations plot
using non-linear regression. Top (maximal response) and bottom
(maximally inhibited response) values were not constrained to
constant values 100 and 0, respectively.
RESULTS
Multidrug Resistance Reversal Assay
Since there is no common pharmacophore determining that a
compound behaves as a P-gp reverser (Yuan et al., 2012) and
due to the wide diversity of chemical structures that interact
with this transporter (Robert and Jarry, 2003) as well as the
lack of information on metabolites from Argentinian flora as
P-gp chemosensitizers, we decided to investigate this effect in
15 plant-derived compounds belonging to different chemical
families obtained from plants from central Argentina (Carpinella
et al., 2002, 2003, 2005; Diaz Napal et al., 2009; Chiari et al.,
2010, 2011; Joray et al., 2011, 2013, 2015; del Corral et al., 2012;
Diaz Napal and Palacios, 2013). Compounds 1–15 were studied
by an MTT assay, in order to evaluate the potentiation of DOX
cytotoxicity in insensitive Lucena 1 cells, which were 35-fold
more resistant to this drug [IC50 = 40.78 (16.60–100.18) µM]
than their parental cell line K562 [IC50 = 1.16 (0.52–2.58) µM].
The combination of the maximum non-toxic concentrations of
the tested compounds with DOX showed the flavonoid 9 and
the lignan 14 as the most effective, enabling the IC50 value of
DOX in Lucena 1 cells to be decreased by a factor of 3.2 and 9.4,
respectively (Table 1). The latter value is similar to that obtained
with verapamil 30 µM (p > 0.05). When 14 was also tested at
28 µM, it caused a 3.4-fold increase in Lucena 1 sensitivity to
DOX (Table 1), indicating that this compound was as active as 9
(p > 0.05). Given the highest effect reached by 14 when tested at
a higher concentration, due to its low cytotoxicity, we selected 14
as the first compound to be further studied. As shown in Table 1,
compound 14 was able to potentiate DOX toxicity in a dose-
dependent manner (b = 0.070; p = 0.013; CI 95% = 0.016 to
0.124) from 7 µM (see also Figure 3). The comparison of the
dose-response curves of DOX alone and in combination with 14
clearly showed the enhancement in DOX cytotoxicity (Figure 3).
It is worth noting that 14 did not increase DOX sensitivity in
K562 (Table 1 and Figure 3), while compounds 6 and 9 caused
a decrease in DOX IC50, with the former also showing reversing
properties in Lucena 1 (Table 1). These results further support
the need to first investigate the activity of compound 14.
We also studied the reversal property of 14 to VLB resistance
in Lucena 1 [VLB IC50 values of 2.49 µM (0.34–18.20) and
0.24 µM (0.04–1.89) in Lucena 1 and K562, respectively]. When
14 was co-administered with VLB, it significantly restored the
sensitivity of theMDR cell line to VLBwith a reversal fold activity
of 60.20 (p < 0.0001), while the RF value in K562 was 9.63
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TABLE 1 | Reversal effects of compounds 1-16 on P-gp mediated
resistance of Lucena 1 cells.
Compounds (µg mL−1 / µM) RF
K562 Lucena 1
1 (40/263) 0.87 ± 0.09 0.59 ± 0.21
2 (10/56) 17.00* ± 0.25 1.23 ± 0.17
3 (40/168) 0.83 ± 0.12 1.35* ± 0.14
4 (40/208) 3.92* ± 2.83 0.82** ± 0.07
5 (10/36) 1.63 ± 1.05 0.93 ± 0.22
6 (2.5/10) 3.48* ± 0.67 1.73* ± 0.22
7 (20/78) 1.11 ± 0.19 0.53 ± 0.17
8 (40/147) 0.29 ± 0.08 0.68 ± 0.10
9 (10/28) 1.83* ± 0.52 3.19** ± 0.24
10 (20/74) 1.00 ± 0.01 0.71 ± 0.12
11 (5/17) 1.18 ± 0.18 0.47** ± 0.04
12 (2.5/8) 2.17** ± 0.64 0.84 ± 0.19
13 (20/45) 0.49* ± 0.04 1.11 ± 0.17
14 (40/112) 1.11 ± 0.15 9.42* ± 4.92
(20/56) − 2.57** ± 0.20
(10/28) − 3.44** ± 0.86
(5/14) − 1.90* ± 0.28
(2.5/7) − 1.61* ± 0.18
(1.25/3.5) − 0.92* ± 0.02
15 (0.3/0.55) 5.68** ± 3.31 0.67* ± 0.23
16 (12/28) 17.26* ± 3.17 96.79** ± 4.60
(6/14) 1.05 ± 0.14 22.66** ± 2.68
(3/7) − 5.54* ± 0.59
(1.5/3.5) − 3.49* ± 0.27
(0.75 /1.75) − 3.16* ± 0.48
(0.37/0.87) − 1.90* ± 0.21
(0.18/0.43) − 1.37*** ± 0.05
(0.09/0.21) − 1.37* ± 0.14
(0.04/0.11) − 1.42* ± 0.14
(0.02/0.055) − 0.79* ± 0.04
Verapamil (15/30) 1.24 ± 0.49 13.88* ± 4.79
(0.054/0.11) − 1.34*** ± 0.06
(0.027/0.055) − 1.17 ± 0.17
Reversal Fold (RF) values were calculated as IC50 of DOX alone/IC50 of DOX in the
presence of the tested compounds. Statistical comparisons between IC50 of DOX alone
or with compound in each treatment were performed by one-tailed paired t-test. Results
represent the mean ± SE. ***p < 0.001, **p < 0.01 and *p < 0.05.
(p < 0.05). Verapamil induced a decrease in the VLB IC50 of
49.17 (p< 0.0001) and 2.35-fold (p< 0.05) in Lucena 1 and K562,
respectively.
Doxorubicin Intracellular Accumulation
Assay
Based on the results of the reversal assay, we evaluated the
capacity of 14 to inhibit the function of P-gp by measuring the
intracellular accumulation of DOX by flow cytometry.
To determine the desirable period of incubation, the uptake
profile of DOX was first investigated at different periods of
pre-incubation with 14. As seen in Figure 4A, a significant
FIGURE 3 | Dose-response curves for cytotoxicity of doxorubicin
(DOX) in Lucena 1 and K562 cells with and without pinoresinol (14) as
determined by the resistance reversal assay. Values are expressed as
mean ± SE of at least three independent experiments.
increase (p < 0.01) in DOX accumulation by a factor of
1.3-fold was observed in Lucena 1 cells in the absence of
pre-incubation compared with ethanol control cells, which
showed the same rate of accumulation as untreated cells.
The increase in DOX-associated MFI remained till 48 h of
pre-incubation achieving a 1.4-fold increase. These values
compared favorably with the 1.4 and 1.8-fold increase observed
with verapamil at 0 and 48 h, respectively (p > 0.05). The
highest difference in DOX accumulation with respect to the
negative control was observed at 1 h pre-incubation (p <
0.001), at which time the highest percentage of inhibition
related to verapamil was obtained (79% inhibition). Given
these results, the selected pre-incubation time for further
analysis was set at 1 h. No such increase in MFI was
observed in K562 cells treated with 14 or with verapamil
(Figure 4B).
The time course of DOX accumulation was further
investigated. DOX- associated MFI increased in a time-
dependent response in Lucena 1 treated with 14 with
significantly higher values than that of Lucena 1 ethanol-
treated cells (Figure 5). At 20min, it was observed that 14 fully
restored the presence of DOX within Lucena 1 cells (p < 0.05),
reaching the MFI values observed in K562 (p > 0.05). This
tendency was maintained over the whole period of time. The
highest difference in MFI values in relation to the Lucena 1
ethanol control was observed at 1 h (Figure 5), determining that
1 h incubation with DOX was adequate.
To further understand the mechanism of P-gp inhibition, we
studied the behavior of 14, monitoring the intracellular retention
of DOX by flow cytometry. Increasing the concentrations of
14, the values of MFI remained the same, while the Michaelis-
Menten constant (Km) increased, as observed in the family of
straight lines passing through the same point of the vertical
axis (Figure 6). This plot indicated that 14 was a competitive
inhibitor.
Following primary screening, 14was assayed at serial dilutions
to determine its minimum effective concentration (MEC). It
significantly increased the intracellular accumulation of the
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FIGURE 4 | Flow cytometric analysis of the effect of pinoresinol (14) on the intracellular accumulation of doxorubicin (DOX). (A) Lucena 1 and (B) K562
cells were pre-incubated at different times with medium containing 14 at 112 µM before 1 h exposure to DOX. Each bar represents the mean ± SE. Significant
differences from the ethanol control were determined at each time by using unpaired one-tailed Student’s t-test (***p < 0.001, **p < 0.01, *p < 0.05).
substrate in Lucena 1 from 56 µM onwards (p < 0.05), with
no differences with respect to verapamil (p > 0.05) (data not
shown). No dose-dependency was observed. At the concentration
mentioned and up to the maximum concentrations evaluated, no
increase was observed in DOX accumulations in K562 (p > 0.05)
(data not shown).
Modulation of Doxorubicin Efflux
Since it was determined that 14 is capable of reversing DOX
accumulation deficit, it was investigated whether this effect can
be maintained after removing DOX from themedium. Figure 7A
shows that 14 clearly increased DOX retention in Lucena 1
cells. At 30min, the DOX-associated MFI increased 1.8-fold in
comparison with control cells (p < 0.05) with similar activity
to that observed with verapamil (p > 0.05). The effectiveness of
14 was maintained until the end of the experiment (Figure 7A).
Neither 14 nor verapamil showed any significant effect on DOX
eﬄux in K562 cells (Figure 7B).
The minimum effective concentration (MEC) corresponded
to 56 µM (p < 0.01), with significant differences with respect
to verapamil (p < 0.01; Figure 8). A dose-dependent effect was
observed (b= 0.037; p ≤ 0.0001; CI 95%= 0.023 to 0.051).
Modulation of Rhodamine 123 Efflux
The ability of compound 14 to prevent the extrusion of another
P-gp substrate, Rho 123, was further evaluated by flow cytometry.
As shown in Figure 9A, exposure of Lucena 1 cells to 14
enhanced intracellular Rho 123 intensity 1.5-fold. This effect was
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FIGURE 5 | Time course of doxorubicin (DOX) accumulation in Lucena
1 cells treated with pinoresinol (14) at 112 µM or ethanol (control) and
in K562 cells treated with ethanol at different periods of time. Data are
expressed as mean ± SE. Significant differences at each time were
determined by using two way analysis of variance (ANOVA) followed by the
Bonferroni test (***,†††p < 0.001, ††p < 0.01, *,†p < 0.05); †: differences
between Lucena 1 treated cells and Lucena 1 ethanol control and *:
differences between K562 ethanol control and Lucena 1 ethanol control.
FIGURE 6 | Lineweaver-Burk double reciprocal plot for the kinetic
analysis of pinoresinol (14). Lucena 1 cells were cultured for 1 h with a
series of concentrations of 14 before 1 h exposure to DOX. The lines were
drawn using linear least squares fit. Values are expressed as mean ± SE.
significantly different from that observed with verapamil and
with TFP, another known P-gp inhibitor (p< 0.01), but to a lesser
extent with the latter. Compound 14 did not induce any increase
in Rho 123-associated MFI in K562 (Figure 9B).
Determination of the ATPase Activity
To further characterize the P-gp-resistance reversal properties
of 14, its influence on basal and verapamil-stimulated ATPase
FIGURE 7 | Flow cytometric analysis of the effect of pinoresinol (14) on
the efflux of doxorubicin (DOX) from (A) Lucena 1 and (B) K562 cells. After
1 h pre-incubation with 14 at 112 µM, verapamil or ethanol, cells were
exposed to DOX for 1 h. Subsequently, cells were washed and then incubated
in the presence of 14 at 112 µM, verapamil or ethanol at various time points in
a DOX-free medium. Data points represent the mean ± SE. Significant
differences from the control were determined by using unpaired one-tailed
Student’s t-test (**p < 0.01, *p < 0.05).
activity was determined. As observed in Figure 10, compound
14 mildly stimulated P-gp-ATPase activity with a maximum of
29.49 ± 4.55% at 66.7 µM, a lower value than that observed
with verapamil. It was also observed that 14 antagonized the
verapamil-stimulated ATP hydrolysis with an IC50 of 20.89 µM
(17.39–23.61).
It is worth mentioning that 14 had no effect on the ATPase
activity of control membranes up to 600 µM and that a
complete inhibition of verapamil-stimulated ATPase hydrolysis
was observed with CsA (data not shown).
Molecular Modeling
The estimated free energy of binding and the corresponding
inhibition constants obtained for the (+)- and (−)-pinoresinol
(14) are summarized inTable 2, together with the values obtained
for the model substrate DOX, compound 2, as the negative
control and the mild and powerful known inhibitors verapamil
and tariquidar. As observed, there is a small difference in the
estimated binding energies (0.14 kcal/mol) between (+)- and
(−)-pinoresinol. Both enantiomers went to the same site, with
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FIGURE 8 | Effect of a series of concentrations of pinoresinol (14) on
the efflux of doxorubicin (DOX) in Lucena 1 cells. Data points represent
the mean ± SE. Significant differences from the control were determined by
using unpaired one-tailed Student’s t-test (***p < 0.001, **p < 0.01,
*p < 0.05).
slight differences in the pose. The binding mode of the subject
compound 14 is shown on Figure 11, revealing as main contacts
S222, A223, K234, F303, Y307, V310, L339, and F343, most of
which are residues from TMH 4, 5 and 6. Almost all of these are
also involved in binding the reference inhibitor verapamil and
part of them also to the powerful inhibitor tariquidar. The KI
obtained for tariquidar in the sub-nM order (Table 2) is close to
that experimentally found [58], while the value obtained for the
negative control, 2 is almost 100µM,which is inactive in practice,
matching that observed experimentally.
On the other hand, it was observed that the affinity of 14 for
the NBD region was substantially lower than that for the region
in the TMD.
As also observed in Table 2, compound 16 was found to
have the most favorable binding energy among the set of
pinoresinol derivatives that were evaluated with the intention
of improving the activity of 14. Compound 16 was also
found to be 0.45 kcal/mol more favored than its own
enantiomer 16a [derivative of the (−)-pinoresinol], showing
a still mild but clearer stereospecificity than for the case of
14. This result encouraged the further experimental study of
compound 16.
The poses of 14, 16 and tariquidar are superimposed on
Figure 12C. Compounds 14 and 16 overlap with the binding
region of tariquidar in one of the homolog halves at the top of
the inverted “V” formed by the TMHs. This region overlaps with
a secondary DOX binding site (0.5 kcal/mol less stable than the
main site i.e., the one with the more negative binding energy,
reported in Table 2; see also Figures 12A–C). As previously
FIGURE 9 | Flow cytometric analysis of the effect of pinoresinol (14) on
the efflux of rhodamine 123 (Rho 123) in (A) Lucena 1 and (B) K562 cells.
Both cell lines were pre-incubated with medium containing 14 at 112 µM,
verapamil, trifluoperazine (TFP) or ethanol and then allowed to accumulate Rho
123 over 30 min. After washing, cells were incubated in probe-free medium in
the presence of the assayed compounds for a further 30 min to allow Rho 123
extrusion. Each bar represents the mean ± SE. Significant differences from the
control were determined by using unpaired one-tailed Student’s t-test (***p <
0.001, **p < 0.01, *p < 0.05).
discussed (Jara et al., 2013), the binding of the subject compound
seems to be just the first step of a complex process involving long
range conformational changes induced in the transporter. In this
context, the fact of finding coincidences in the main contacts
compared to those observed for known powerful inhibitors
would be a promising feature, besides the binding energies
themselves.
Study on the Surface Expression of P-Gp
P-gp expression at the membrane surface was lower in Lucena 1
cells treated with 14 compared to the control group measured at
48 h (Figure 13A).
No suppression of P-gp presence was observed in the outer
membrane in K562 cells at the study times (Figure 13B).
In vitro Activity Of
1-Acetoxy-(+)-Pinoresinol (16)
The pinoresinol derivative 16, which showed the most promising
activity in silico (in terms of binding energy, Table 2), showed
an increase in DOX cytotoxicity by a factor of 22.7 at 14 µM
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FIGURE 10 | Effect of 14 on ATPase activation and inhibition. Data
points represent the mean ± SE.
TABLE 2 | Brief summary of docking results.
Compounds Estimated free energy Inhibition constant
of binding (kcal/mol) KI (nM)
DOX −8.13 1100
Rho 123 −8.08 1200
2 −5.66 71580
16 −9.17 191
16a −8.72 402
1-hydroxy-(+)-pinoresinol −8.59 505
Phylligenin −8.84 338
14 (+)-pinoresinol −8.53 540
14 (-)-pinoresinol −8.39 711
pinoresinol diglucoside −8.26 881
pinoresinol 4-glucoside −8.55 540
Verapamil −9.01 249
Tariquidar −12.36 0.32
and 1.4 at 0.11 µM (Table 1). There was no significant difference
in relation to verapamil at 30 and 0.11 µM with 16 applied
at 14 and 0.11 µM, respectively (p > 0.05). At 14 µM, no
potentiation was observed in DOX activity in K562 cells (p >
0.05). When tested at the maximum non-toxic concentration (28
µM), it caused a 96.8-fold sensitization to DOX in Lucena 1,
while a 17.3-fold activity was observed in K562, meaning that the
shift in the IC50 of DOX was not only due to P-gp inhibition.
For this reason, this concentration was not used in further
assays.
In the accumulation assay, 16 significantly increased the
DOX-associated MFI in Lucena 1 from 0.87 µM (p < 0.05) with
no difference with respect to verapamil (p > 0.05; Figure 14).
As also occurred with 14, no dose-dependency and no increase
in DOX accumulation were observed in K562 (p > 0.05) (data
not shown) at the MEC and up to the maximum concentration
evaluated.
Cytotoxicity on Peripheral Blood
Mononuclear Cells (PBMC)
To determine whether 14 or 16 were toxic on non-tumoral
human cells, PBMC were obtained. These cells were considered
the most adequate in relation to the type of tumor cells evaluated
in this study. An MTT assay showed that 14 and 16 displayed
IC50 values of 216.25 µM (125.93–371.35) and 102.57 µM
(48.60–216.45), respectively.
DISCUSSION
P-gp modulation is gaining more and more ground in drug
discovery due to the clinical importance of this pump owing
to its association with MDR (Loo and Clarke, 1999). With the
aim of finding novel inhibitors of P-gp function, we screened
15 bioactive plant-derived principles obtained in the laboratory.
Compound 14 (Figure 1) showed the highest effectiveness in
the reversal assay, potentiating DOX cytotoxicity in Lucena 1
cells from 7 µM (Table 1). When applied at 112, 28 and 14
µM, it showed a comparable effect in circumventing the MDR
phenotype to that of verapamil at 30 µM (p > 0.05). When
the combination of 14 and DOX was evaluated on the sensitive
K562 cell line, no decrease was seen in the inhibitory value
of the chemotherapeutic drug, and thus any other interaction
between these compounds different from P-gp inhibition was
discarded. It was remarkable that compounds 8 and 10 did
not cause any effect in DOX toxicity, while 11 decreased DOX
sensitivity (p < 0.01). Although these compounds have been
described as P-gp inhibitors (Deferme and Augustijns, 2003; Ofer
et al., 2005; Borska et al., 2012; Saeed M et al., 2015), in some
assays no activity or stimulatory activity was found (Deferme
and Augustijns, 2003; Khantamat et al., 2004; Katayama et al.,
2007; Wu et al., 2016), which agrees with our findings. These
contradictory observations have been previously reported by
other authors (Di Pietro et al., 2002; Deferme and Augustijns,
2003) and could be due to the different concentrations used in
the experiments (Yuan et al., 2012), the type of cancer cells tested
(Di Pietro et al., 2002) and differences in the interactions between
the flavonoids and P-gp depending on the substrate used in the
experiments (Di Pietro et al., 2002; Eid et al., 2015). On the other
hand, the chalcone 6 was capable of potentiating DOX toxicity,
not only by interfering with P-gp, as was previously determined
(Chieli et al., 2012), but also and mainly, by some additional
mechanism as deduced by the RF observed in K562 (Table 1).
The effective compound 14 also potentiated the cytotoxicity of
VBL in Lucena 1 cells (RF = 60) and in K562 to a lesser extent
(RF = 9). The RF of 14 was comparable to that of verapamil
(RF = 49) (p > 0.05), which also decreased VLB IC50 in K562
(RF = 2). These results showed that, besides the inhibition
on P-gp mediated transport, which seems predominant, 14
and verapamil also induce another kind of interaction. It was
previously reported that verapamil enhanced the cytotoxicity of
VLB not only in the resistant P388/VCR cell line but also in the
sensitive cell line P388 (Tsuruo et al., 1981).
The activity demonstrated by 14 in the MTT assay was
confirmed by examining the intracellular accumulation of DOX,
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FIGURE 11 | Binding mode of the lowest energy conformation of (+)-pinoresinol (14) showing the main contacts of 14 with residues from TMH 4, 5,
and 6.
which specifically reflects the reversion of drug transport out
of cells. As seen in Figure 4A, compound 14 showed a clear
increase in intracellular DOX-associated fluorescence in the
absence of pre-incubation, an effect that remained till the end
of the study. Huang et al. (2013) established that compounds
with an activity >30% of the maximal activity exerted by
verapamil were considered as P-gp inhibitors. In our results,
14 showed inhibitory activity throughout the course of the
study (inhibition at 0 and 48 h = 60 and 55%, respectively),
with a maximum effect at 0.5 and 1 h of experiment (73 and
79% of inhibition, respectively). These values showed that the
activity of 14 is particularly noteworthy, and the long-term
effectiveness suggested that the lignan was not inactivated by
cellular metabolism. It is important to note that a decrease in the
superficial expression of the pump was observed at 48 h, meaning
that at this time a sum of events could influence the results.
On the other hand, 14 showed no effect on DOX accumulation
when tested in K562 cells (Figure 4B). This strongly supports
the proposition that 14 reverses the eﬄux of DOX out of
the cells specifically by interfering with P-gp function. It has
been previously described that (+)-pinoresinol increased the
intracellular accumulation of calcein-AM when applied at 50
and 100 µM (Tamaki et al., 2008). However, no additional
information about the P-gp-mediated resistance-reversing effect
of this compound has been reported and there is no evidence
showing the mechanism underlying this property. As far as we
know, there are no reports evaluating the racemic mixture.
The time course study showed that 14 was effective at
retaining DOX in Lucena 1 cells at 20 min from the beginning
(p < 0.05; Figure 5), showing that short-term treatment with the
modulator leads to effectiveness. The fact that the intracellular
DOX fluorescence intensities obtained in Lucena 1 treated with
14 were similar to those obtained in K562 (p > 0.05) showed the
potency of 14 for fully blocking the eﬄux of the drug.
To obtain further information about the type of inhibition
exerted by 14, the kinetic behavior of DOX accumulation was
analyzed by the Lineweaver-Burk double reciprocal method
(Figure 6), which showed that the lignan was a competitive
inhibitor of P-gp.
The addition of 14 from 56µM significantly enhanced cellular
DOX accumulation compared to control cells with an 80%
inhibition with respect to verapamil. This MEC differs from that
obtained in the resistance reversal assay, in which it was observed
that 14 was active from 7 µM (Table 1). This discrepancy,
also reported by other authors (Schuurhuis et al., 1989; Lan
et al., 1996), seems not to be related to the different incubation
periods or DOX concentrations used in both experiments, since
it was previously demonstrated that these parameters did not
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FIGURE 12 | Two different views of the lowest energy docked structure of 14. (A) Point of view looking to the inverted “V” within the bilayer plane, the same
point of view as in Figure 11 and (B) looking from the intracellular side to outside (perpendicular to the bilayer plane). The binding pose of 14 (ball and sticks) is
compared to the main and secondary sites of Rhodamine 123 (yellow tubes) and DOX (green tubes). The sites of lowest energy are opposite for Rho 123 and DOX,
and the energy difference between the secondary site and the main (reported on Table 2) is below 0.5 kcal/mol in both cases. (C) Superimposition of the lowest
energy poses of 14 (orange), 16 (red), and the known inhibitors verapamil (lime) and tariquidar (violet).
influence the results (Pereira and Garnier-Suillerot, 1994; Lan
et al., 1996). Lan et al. (1996) explained this discrepancy stating
that the amplitude of the reversion of DOX resistance exerted
by a compound was higher than the increase of its intracellular
accumulation. This difference would be supported by previous
findings regarding subcellular DOX localization (Schuurhuis
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FIGURE 13 | Effect of pinoresinol (14) on the surface expression of P-glycoprotein by flow cytometric analysis. (A) Lucena 1 and (B) K562 cells were
stained with FITC-labeled mouse anti-human P-glycoprotein antibody at 24 and 48 h. Unstained cells are shown with red histogram, stained cells with blue histogram
and cells stained and treated with 14 at 112 µM are shown with green histogram. Histograms are representative of three independent experiments.
FIGURE 14 | Effect of a series of concentrations of
1-acetoxy-(+)-pinoresinol (16) on the accumulation of doxorubicin
(DOX) in Lucena 1 cells. Significant differences from the control were
determined by using unpaired one-tailed Student’s t-test (***p < 0.001,
**p < 0.01, *p < 0.05).
et al., 1989, 1993; Pereira and Garnier-Suillerot, 1994; Lan et al.,
1996). In the accumulation assays, flow cytometry measures
all the DOX inside the cell, including that sequestered inside
cytoplasmic vesicles attributable to the pumping of the drug into
them by P-gp (Lan et al., 1996; Munteanu et al., 2006; Yu et al.,
2008), while the phenomenon of cell killing is only influenced
by the presence of DOX in the nucleus (Yu et al., 2008). In
the absence of 14, a small concentration of the cytotoxic agent
trapped in the vesicles will be considered in the measurements
of fluorescence, resulting in a lower difference in comparison to
the treatment. The possible effect of 14 in blocking both plasma
and vesicular membrane P-gp would lead to an increase of DOX
in the nucleus, as is also observed with verapamil (Schuurhuis
et al., 1993). In this situation, the change in DOX toxicity will be
greater. These observations indicated that 14 increased not only
DOX accumulation but also its toxicity.
Although a dose- response relationship was not clearly seen
in the accumulation assay, this could be seen in the reversal and
eﬄux assays, indicating that the behavior of compound 14 was
dose-dependent. Similar results were previously obtained with
some thioxanthones for the reversal and accumulation assays
(Palmeira et al., 2012b).
The results obtained in the eﬄux assays showed that
compound 14 increased the accumulation of DOX to a slightly
higher extent than that of Rho 123 [retention increased 1.8
(Figure 7A) and 1.5 times (Figure 9A), respectively at 30 min
of experiment]. This suggested that 14 is a P-gp inhibitor which
shows a different level of potency depending on the substrate
used. Rho 123 binds to the R site (Loo and Clarke, 2014), while
the binding site for DOX is predominantly located at the H-site
(Zeino et al., 2015). Overlapping but distinct drug specificities of
these sites (Shapiro and Ling, 1997) would explain the different
level of effectiveness exerted by 14. Docking studies (Figure 12C)
showed that 14, 16 and tariquidar bind to P-gp in the H binding
site, located on TMH 4, 6, 10, 11, and 12 (Gutmann et al., 2010),
agreeing with previous findings reported for tariquidar (Li et al.,
2015). However, due to the similarity in the binding energies of
both substrates and the small differences in the affinities of the
main and secondary sites, the docking results seem not to shed
light on this issue.
It has been previously reported that other lignans, such as
schisandrin A (Huang et al., 2008; Xia et al., 2015), schisandrin
B (Qiangrong et al., 2005; Huang et al., 2008), schizandrol A
(Huang et al., 2008), nirtetralin, niranthin, phyllanthin, and
phyltetralin (Leite et al., 2006), arctigenin, arctiin, matairesinol,
(iso)lappaol A, lappaol C and lappaol F (Nabekura et al., 2008; Su
et al., 2015) showed an inhibitory effect against P-gp activity. It is
worth noting that the closely related lignan (-)-sesamin increased
the accumulation of daunorubicin from a concentration of 50
µM in KB-C2 cells overexpressing P-gp (Nabekura et al., 2008).
To gain deeper insight into the characteristics of the reversal
activity of 14 on the functional aspect of P-gp, its effects on
P-gp-ATPase activity were investigated as well as its binding
mode to the glycoprotein. Examining the effects of 14 on P-
gp ATPase, it was observed that it slightly activated the basal
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ATP hydrolysis and antagonized verapamil-stimulated ATPase
activity (Figure 10). The latter effect arose from docking analysis.
In silico analysis determined that 14 binds to P-gp in the apex
of the V-shaped transmembrane barrels, a site proposed as key for
substrate/inhibitor recognition. As seen in Figure 11, 14 binds
to the aromatic aminoacids located in TMH 4, 5 and 6. This
region also found for 16, clearly overlaps with that found for
verapamil and for contacts of tariquidar with one of the homolog
halves of the TMB (Figure 12). Most of the residues involved
in the binding of 14 were also contacts of this last reference
inhibitor. Most of these residues were proposed as relevant in the
binding of inhibitors in experimental and computational bases, as
previously discussed (Jara et al., 2013). These results would shed
some light on the nature of its interaction with P-gp at molecular
level and merit further mechanistic and kinetic studies.
The effect of 14 on the surface expression of P-gp was
determined by flow cytometry. The experiments showed that
treatments with 14 resulted in less P-gp at the Lucena 1 cell
membrane at 48 h. These results would indicate that 14 countered
drug resistance, not only by modulating P-gp function but also
by interfering with the presence of P-gp in the cell surface, which
also prevents drug eﬄux (Loo and Clarke, 1997, 2000).
Considering compound 14 as a promising lead compound,
virtual derivatives with pinoresinol scaffold were submitted to
molecular modeling studies. Based on the results obtained,
compound 16 deserved further evaluation since its estimated
free energy of binding (−9.17 kcal/mol) was similar to or even
better than that of verapamil (−9.01 kcal/mol). The result showed
that 16 was 64 times more effective than 14 according to the
MECs obtained by the reversal (0.11 and 7 µM, respectively)
and the accumulation assays (0.87 and 56 µM, respectively),
thus demonstrating outstandingly improved activity. The same
explanation of the discrepancy in the MECs of 14 obtained
by the reversal and accumulation assays could also be applied
to explain the difference obtained with 16. At the minimum
concentration that increased intracellular DOX, 16 showed 62%
activity compared to verapamil while it showed superior activity
to the reference compound (141%) when cells were exposed
to 14 µM (Figure 14). The absence of an increase in DOX
accumulation in K562 indicated that 16 specifically blocked eﬄux
mediated by P-gp. Further analyses are needed to characterize the
activity and the mechanism of action of 16 in more detail.
The IC50 of 216.2 and 102.6 µM displayed by 14 and 16,
respectively, on PBMC indicated an absence of cytotoxicity,
based on the statement of the US National Cancer Institute plant
screening program which established as cytotoxic those pure
compounds with mean toxicity values below 10 µM (Kuete et al.,
2014). It is important to note that the IC50 values obtained were
much higher than the effective concentrations observed for both
lignans. In addition to the presence of 14 in Melia azedarach
(Carpinella et al., 2003), this compound and also 16 are present,
in considerable proportions, in virgin olive oil which is an
important component of the diet (Fini et al., 2008; López-Biedma
et al., 2016). A case-control study of the protective role of
pinoresinol in breast cancer risk demonstrated that the median
daily consumption of 14 was 60 µg (Torres-Sanchez et al., 2009).
CONCLUSION
Our findings demonstrated that compound 14 and its derivative
16 are likely to be promising P-gp chemosensitizers. This
property, the low cytotoxicity demonstrated by these lignans
and its presence in the daily diet, position them as potential
candidates for developing compounds to use in combination with
anticancer drugs, which could lead to significant advances in
leukemia therapies.
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